-
- EXPLORE
-
-
-
-
-
-
-
-
-
Actueel
-
Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List PriceIonis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024. First FDA-Approved Olezarsen Therapy for...0 Reacties 0 aandelen 556 Views 0 voorbeeldPlease log in to like, share and comment!
-
PARSABIV (Etelcalcetide Hydrochloride Injection) – Mechanism of Action and DosageBelow is a detailed description of the mechanism of action and dosage of PARSABIV (Etelcalcetide Hydrochloride Injection): Mechanism of Action PARSABIV is a synthetic calcimimetic peptide drug. Its active ingredient, etelcalcetide, specifically binds to and activates the calcium-sensing receptors (CaSR) on the surface of parathyroid cells. By mimicking the physiological effects of increased...0 Reacties 0 aandelen 650 Views 0 voorbeeld
-
0 Reacties 0 aandelen 164 Views 0 voorbeeld
Meer blogs